Research results on Cogterra, a digital therapeutic device, officially recognized as a national strategic R&D achievement.
Cogthera, a digital therapeutic device for patients with mild cognitive impairment (MCI), has been officially recognized by the government as a full-cycle research and development achievement accumulated through the inter-ministerial full-cycle medical device research and development project.
Digital healthcare specialist Imocog (Co-CEOs Lee Jun-young and Noh Yu-heon) announced on the 22nd that Co-CEO Noh Yu-heon, the principal investigator of the Cogterra research project, received the Korea Institute of Technology Planning and Evaluation Director's Award (Ministry of Trade, Industry and Energy Field Specialized Institution Director's Award) at the '2025 Inter-Ministry Medical Device R&D Awards' representing the achievement.
This awards ceremony is an official government event that comprehensively evaluates the achievements of the Inter-Ministry Full-Cycle Medical Device Research and Development Project (2020-2025), jointly promoted by four ministries: the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health and Welfare, and the Ministry of Food and Drug Safety. It selects and awards the principal investigators who have achieved outstanding results across the entire R&D cycle, from medical device research and development through clinical trials and regulatory approvals. The awards ceremony took place at 10:00 AM on the 22nd at the Sapphire Hall of the Lotte Hotel in Seoul.
Cogthera is Korea's first digital therapeutic device for mild cognitive impairment (MCI) designed to allow patients to perform cognitive intervention treatment in their daily lives according to a prescription from a medical professional. Based on clinical evidence, it obtained approval from the Ministry of Food and Drug Safety (MFDS) in May 2025 and is evaluated as a case with full-cycle results that range from research, clinical trials, and approval to actual application in the medical field.
Imocog has accumulated research, clinical, and licensing achievements for Cogterra through inter-ministerial projects. Based on these research achievements, Cogterra is currently being prescribed in medical settings, including major general hospitals in Korea, and is steadily expanding its scope of application.
This study was conducted through joint research with Gil Medical Foundation, Seoul Metropolitan City Boramae Hospital, Yonsei University Wonju Industry-Academic Cooperation Foundation, and Yonsei University Wonju Severance Christian Hospital, and has verified the possibility of actual medical application of digital therapeutic devices based on close collaboration with clinical sites.
The project is a national medical device R&D program that was implemented over six years from 2020 to 2025 with a total budget of KRW 1.2 trillion. Among the 437 projects, the Cogterra research project was included in the '10 representative projects' selected through a comprehensive evaluation of research performance and technological and social impact.
Co-CEO Noh Yoo-heon said, “This award is the result of the official recognition of the research achievements of the digital therapeutic device Cogthera from a full-cycle R&D perspective across all ministries,” and added, “The team worked together to create results that were connected to the medical field through research, clinical trials, and licensing.”
Co-CEO Lee Jun-young emphasized, “Since receiving approval from the Ministry of Food and Drug Safety, Cogthera has been smoothly applied in actual medical settings with prescriptions being made,” and “This award is an important milestone that shows that digital therapeutic devices are moving beyond research achievements and establishing themselves as field-centered treatment technologies.”
With this award as a momentum, Imocog plans to continue expanding the process of connecting the research and development of digital therapeutic devices, centered around Cogterra, to the medical field.
You must be logged in to post a comment.